1. Home
  2. RUBI vs ARTL Comparison

RUBI vs ARTL Comparison

Compare RUBI & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rubico Inc.

RUBI

Rubico Inc.

N/A

Current Price

$1.37

Market Cap

1.7M

ML Signal

N/A

Logo Artelo Biosciences Inc.

ARTL

Artelo Biosciences Inc.

N/A

Current Price

$2.28

Market Cap

1.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RUBI
ARTL
Founded
2022
2011
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7M
1.4M
IPO Year
2022
2014

Fundamental Metrics

Financial Performance
Metric
RUBI
ARTL
Price
$1.37
$2.28
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 5.2M
24.3K
Earning Date
11-18-2026
11-24-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$0.19
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.10
$0.52
52 Week High
$6.69
$179.19

Technical Indicators

Market Signals
Indicator
RUBI
ARTL
Relative Strength Index (RSI) 55.05 39.03
Support Level $0.91 $2.05
Resistance Level $2.01 $6.81
Average True Range (ATR) 0.20 0.23
MACD 0.14 0.07
Stochastic Oscillator 45.74 44.97

Price Performance

Historical Comparison
RUBI
ARTL

About RUBI Rubico Inc.

Rubico Inc is an international provider of crude oil transportation services. The Company is engaged in the ownership and operation of a fleet of tanker vessels designed for enhanced fuel efficiency and reduced greenhouse gas emissions, incorporating environmentally friendly technologies.

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

Share on Social Networks: